Unknown

Dataset Information

0

Corrigendum: 7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir.

ABSTRACT:

SUBMITTER: Ziegler RE 

PROVIDER: S-EPMC8097624 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Corrigendum: 7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir.

Ziegler Robert E RE   Desai Bimbisar K BK   Jee Jo-Ann JA   Gupton B Frank BF   Roper Thomas D TD   Jamison Timothy F TF  

Angewandte Chemie (International ed. in English) 20180916 46

Similar Datasets

Unknown 7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir.
| S-EPMC6033037 | biostudies-literature
Unknown Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
| S-EPMC4158172 | biostudies-literature
Unknown Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
| S-EPMC3754328 | biostudies-literature
Unknown Approaches to the synthesis of a novel, anti-HIV active integrase inhibitor.
| S-EPMC3846259 | biostudies-literature
Unknown Synthesis of Dolutegravir Exploiting Continuous Flow Chemistry.
| S-EPMC10442919 | biostudies-literature
Unknown Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
| S-EPMC8765460 | biostudies-literature
Unknown Allosteric inhibitor development targeting HIV-1 integrase.
| S-EPMC3115487 | biostudies-literature
Unknown Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
| S-EPMC3187526 | biostudies-literature
Unknown Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.
| S-EPMC3797783 | biostudies-literature
Unknown Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants.
| S-EPMC11803526 | biostudies-literature